MovDisordV3, PascalFrancis, Curation, bibRecord, 001545

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease

Identifieur interne : 001545 ( PascalFrancis/Curation ); précédent : 001544; suivant : 001546

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease

Auteurs : XUEMEI HUANG [États-Unis] ; HONGLEI CHEN [États-Unis] ; William C. Miller [États-Unis] ; Richard B. Mailman [États-Unis] ; Jennifer L. Woodard [États-Unis] ; Peter C. Chen [États-Unis] ; DONG XIANG [États-Unis] ; Richard W. Murrow [États-Unis] ; Yi-Zhe Wang [États-Unis] ; Charles Poole [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0181697

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Lipoprotéine, Cholestérol, Apolipoprotéine E, Statine dérivé, Etude cas témoin.

English descriptors

KwdEn :
- Apolipoprotein E, Case control study, Cholesterol, Lipoprotein, Nervous system diseases, Parkinson disease, Statin derivative.

Abstract

The apolipoprotein E (APOE) e2 allele has been associated with both Parkinson's disease (PD) and lower low-density lipoprotein cholesterol (LDL-C). We tested the hypothesis that lower LDL-C may be associated with PD. This case-control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age, gender, smoking status, and use of cholesterol-lowering agents. Lower LDL-C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL-C (≥38 mg/dL), the OR was 2.2 (95% CI = 0.9-5.1) for participants with LDL-C of 115 to 137, 3.5 (95% CI = 1.6-8.1) for LDL-C of 93 to 114, and 2.6 (95% CI = 1.1-5.9) for LDL-C of ≤ 92. Interestingly, use of either cholesterol-lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL-C may be associated with higher occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease`
A11	`01`	`1`		`@1 XUEMEI HUANG`
A11	`02`	`1`		`@1 HONGLEI CHEN`
A11	`03`	`1`		`@1 MILLER (William C.)`
A11	`04`	`1`		`@1 MAILMAN (Richard B.)`
A11	`05`	`1`		`@1 WOODARD (Jennifer L.)`
A11	`06`	`1`		`@1 CHEN (Peter C.)`
A11	`07`	`1`		`@1 DONG XIANG`
A11	`08`	`1`		`@1 MURROW (Richard W.)`
A11	`09`	`1`		`@1 WANG (Yi-Zhe)`
A11	`10`	`1`		`@1 POOLE (Charles)`
A14	`01`			`@1 Department of Neurology, University of North Carolina School of Medicine @2 Chapel Hill, North Carolina @3 USA @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 National Institute of Environmental Health Sciences @2 Research Triangle Park, North Carolina @3 USA @Z 2 aut.`
A14	`03`			`@1 Department of Epidemiology, School of Public Health, University of North Carolina @2 Chapel Hill, North Carolina @3 USA @Z 3 aut. @Z 10 aut.`
A14	`04`			`@1 Department of Pharmacology, Neuroscience Center, University of North Carolina School of Medicine @2 Chapel Hill, North Carolina @3 USA @Z 4 aut.`
A14	`05`			`@1 Department of Psychiatry, Neuroscience Center, University of North Carolina School of Medicine @2 Chapel Hill, North Carolina @3 USA @Z 4 aut.`
A14	`06`			`@1 Department of Medicinal Chemistry, Neuroscience Center, University of North Carolina School of Medicine @2 Chapel Hill, North Carolina @3 USA @Z 4 aut.`
A20				`@1 377-381`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000159377420140`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 07-0181697`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The apolipoprotein E (APOE) e2 allele has been associated with both Parkinson's disease (PD) and lower low-density lipoprotein cholesterol (LDL-C). We tested the hypothesis that lower LDL-C may be associated with PD. This case-control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age, gender, smoking status, and use of cholesterol-lowering agents. Lower LDL-C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL-C (≥38 mg/dL), the OR was 2.2 (95% CI = 0.9-5.1) for participants with LDL-C of 115 to 137, 3.5 (95% CI = 1.6-8.1) for LDL-C of 93 to 114, and 2.6 (95% CI = 1.1-5.9) for LDL-C of ≤ 92. Interestingly, use of either cholesterol-lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL-C may be associated with higher occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Lipoprotéine @5 09`
C03	`03`	`X`	`ENG`	`@0 Lipoprotein @5 09`
C03	`03`	`X`	`SPA`	`@0 Lipoproteina @5 09`
C03	`04`	`X`	`FRE`	`@0 Cholestérol @2 NK @5 10`
C03	`04`	`X`	`ENG`	`@0 Cholesterol @2 NK @5 10`
C03	`04`	`X`	`SPA`	`@0 Colesterol @2 NK @5 10`
C03	`05`	`X`	`FRE`	`@0 Apolipoprotéine E @5 11`
C03	`05`	`X`	`ENG`	`@0 Apolipoprotein E @5 11`
C03	`05`	`X`	`SPA`	`@0 Apolipoproteína E @5 11`
C03	`06`	`X`	`FRE`	`@0 Statine dérivé @2 NK @2 FR @5 12`
C03	`06`	`X`	`ENG`	`@0 Statin derivative @2 NK @2 FR @5 12`
C03	`06`	`X`	`SPA`	`@0 Statina derivado @2 NK @2 FR @5 12`
C03	`07`	`X`	`FRE`	`@0 Etude cas témoin @5 13`
C03	`07`	`X`	`ENG`	`@0 Case control study @5 13`
C03	`07`	`X`	`SPA`	`@0 Estudio caso control @5 13`
C07	`01`	`X`	`FRE`	`@0 Lipide @5 37`
C07	`01`	`X`	`ENG`	`@0 Lipids @5 37`
C07	`01`	`X`	`SPA`	`@0 Lípido @5 37`
C07	`02`	`X`	`FRE`	`@0 Encéphale pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
N21				`@1 122`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001776

Links to Exploration step

Pascal:07-0181697

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease</title>
<author><name sortKey="Xuemei Huang" sort="Xuemei Huang" uniqKey="Xuemei Huang" last="Xuemei Huang">XUEMEI HUANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Honglei Chen" sort="Honglei Chen" uniqKey="Honglei Chen" last="Honglei Chen">HONGLEI CHEN</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Institute of Environmental Health Sciences</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Miller, William C" sort="Miller, William C" uniqKey="Miller W" first="William C." last="Miller">William C. Miller</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Epidemiology, School of Public Health, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B." last="Mailman">Richard B. Mailman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medicinal Chemistry, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Woodard, Jennifer L" sort="Woodard, Jennifer L" uniqKey="Woodard J" first="Jennifer L." last="Woodard">Jennifer L. Woodard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chen, Peter C" sort="Chen, Peter C" uniqKey="Chen P" first="Peter C." last="Chen">Peter C. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dong Xiang" sort="Dong Xiang" uniqKey="Dong Xiang" last="Dong Xiang">DONG XIANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Murrow, Richard W" sort="Murrow, Richard W" uniqKey="Murrow R" first="Richard W." last="Murrow">Richard W. Murrow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Wang, Yi Zhe" sort="Wang, Yi Zhe" uniqKey="Wang Y" first="Yi-Zhe" last="Wang">Yi-Zhe Wang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poole, Charles" sort="Poole, Charles" uniqKey="Poole C" first="Charles" last="Poole">Charles Poole</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Epidemiology, School of Public Health, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0181697</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0181697 INIST</idno>
<idno type="RBID">Pascal:07-0181697</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001776</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001545</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease</title>
<author><name sortKey="Xuemei Huang" sort="Xuemei Huang" uniqKey="Xuemei Huang" last="Xuemei Huang">XUEMEI HUANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Honglei Chen" sort="Honglei Chen" uniqKey="Honglei Chen" last="Honglei Chen">HONGLEI CHEN</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Institute of Environmental Health Sciences</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Miller, William C" sort="Miller, William C" uniqKey="Miller W" first="William C." last="Miller">William C. Miller</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Epidemiology, School of Public Health, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mailman, Richard B" sort="Mailman, Richard B" uniqKey="Mailman R" first="Richard B." last="Mailman">Richard B. Mailman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medicinal Chemistry, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Woodard, Jennifer L" sort="Woodard, Jennifer L" uniqKey="Woodard J" first="Jennifer L." last="Woodard">Jennifer L. Woodard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chen, Peter C" sort="Chen, Peter C" uniqKey="Chen P" first="Peter C." last="Chen">Peter C. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dong Xiang" sort="Dong Xiang" uniqKey="Dong Xiang" last="Dong Xiang">DONG XIANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Murrow, Richard W" sort="Murrow, Richard W" uniqKey="Murrow R" first="Richard W." last="Murrow">Richard W. Murrow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Wang, Yi Zhe" sort="Wang, Yi Zhe" uniqKey="Wang Y" first="Yi-Zhe" last="Wang">Yi-Zhe Wang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poole, Charles" sort="Poole, Charles" uniqKey="Poole C" first="Charles" last="Poole">Charles Poole</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Epidemiology, School of Public Health, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apolipoprotein E</term>
<term>Case control study</term>
<term>Cholesterol</term>
<term>Lipoprotein</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Statin derivative</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Lipoprotéine</term>
<term>Cholestérol</term>
<term>Apolipoprotéine E</term>
<term>Statine dérivé</term>
<term>Etude cas témoin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The apolipoprotein E (APOE) e2 allele has been associated with both Parkinson's disease (PD) and lower low-density lipoprotein cholesterol (LDL-C). We tested the hypothesis that lower LDL-C may be associated with PD. This case-control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age, gender, smoking status, and use of cholesterol-lowering agents. Lower LDL-C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL-C (≥38 mg/dL), the OR was 2.2 (95% CI = 0.9-5.1) for participants with LDL-C of 115 to 137, 3.5 (95% CI = 1.6-8.1) for LDL-C of 93 to 114, and 2.6 (95% CI = 1.1-5.9) for LDL-C of ≤ 92. Interestingly, use of either cholesterol-lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL-C may be associated with higher occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>XUEMEI HUANG</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HONGLEI CHEN</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MILLER (William C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MAILMAN (Richard B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WOODARD (Jennifer L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHEN (Peter C.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DONG XIANG</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MURROW (Richard W.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>WANG (Yi-Zhe)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>POOLE (Charles)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>National Institute of Environmental Health Sciences</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Epidemiology, School of Public Health, University of North Carolina</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Pharmacology, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Psychiatry, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Medicinal Chemistry, Neuroscience Center, University of North Carolina School of Medicine</s1>
<s2>Chapel Hill, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>377-381</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000159377420140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0181697</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The apolipoprotein E (APOE) e2 allele has been associated with both Parkinson's disease (PD) and lower low-density lipoprotein cholesterol (LDL-C). We tested the hypothesis that lower LDL-C may be associated with PD. This case-control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age, gender, smoking status, and use of cholesterol-lowering agents. Lower LDL-C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL-C (≥38 mg/dL), the OR was 2.2 (95% CI = 0.9-5.1) for participants with LDL-C of 115 to 137, 3.5 (95% CI = 1.6-8.1) for LDL-C of 93 to 114, and 2.6 (95% CI = 1.1-5.9) for LDL-C of ≤ 92. Interestingly, use of either cholesterol-lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL-C may be associated with higher occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lipoprotéine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Lipoprotein</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Lipoproteina</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cholestérol</s0>
<s2>NK</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cholesterol</s0>
<s2>NK</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Colesterol</s0>
<s2>NK</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Apolipoprotéine E</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Apolipoprotein E</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Apolipoproteína E</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Statine dérivé</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Statin derivative</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Statina derivado</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude cas témoin</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Case control study</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio caso control</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Lipide</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Lipids</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Lípido</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>122</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001545 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001545 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0181697
   |texte=   Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri